Targeting distribution of anti-CD19(Fab)-LDM: a new anti-lymphoma drug

Aim To study targeting capability of antiCD19(Fab)-LDM to CD19 + B lymphoma cells in vivo and in vitro. Methods Flow cytometry was employed to determine the affinity of Cy5 labeled antiCD19(Fab)-LDP to human lymphoma Raji cells. And the optical imaging system was used to analyze the distribution of Cy5-anti-CD19(Fab)-LDP in lymphomatransplanted xenograft nude mice in vivo. Results The results of flow cytometry demonstrated that Cy5-anti-CD19(Fab)-LDP had remarkable affinity with lymphoma Raji cells; Raji lymphoma xenograft model was established successfully in nude mice and in vivo fluorescence imaging analysis indicated that the antibodydrug conjugates could specially be localized in the target tumor. Conclusion The experiments in vivo and vitro confirm that anti-CD19(Fab)-LDP has remarkable affinity to targeting CD19 + lymphoma cells,and the antibody drugs anti-CD19(Fab)-LDP have the probability to be new drugs for the treatment of malignant lymphoma.